

RECEIVED  
CENTRAL FAX CENTER

AUG 14 2006

Application No.: 10/719,554  
Amendment and Response dated August 14, 2006  
Docket No.: 4727-C2-03-DCL (1321-10)  
Page 4

REMARKS


Claims 1-11 are currently pending in this application. Claim 1 has been amended herein. Applicants respectfully request reconsideration of the application based on the above amendments and the following remarks.

Applicants would like to take this opportunity to thank the Examiner for contacting Applicants' representative on August 11, 2006 to suggest an amendment to claim 1, which would place the application in condition for allowance. In particular, Applicants have amended claim 1 to further define the salicylic acid derivatives. Amended claim 1 requires the salicylic acid derivative to be "selected from the group consisting of salicylic acid, acetylsalicylic acid, diflunisal, salsalate, olsalazine and sulfasalazine." This amendment is supported by disclosure appearing on page 5 of the application, as filed.

In view of the above, Applicants respectfully submit that the application is now in condition for favorable consideration and allowance.

Should the Examiner have any questions or comments concerning the above, the Examiner is respectfully invited to contact the undersigned attorney at the telephone number given below.

Respectfully submitted,

  
Jamie M. Larman  
Registration No.: 48,623  
Attorney for Applicants

Warner-Lambert Company, LLC  
201 Tabor Road, 56-2S  
Morris Plains, NJ 07950  
(973) 331-1700